1. List Prices and Why They Are Not What Patients Pay: WAC, Net Price, and PBM Rebates
The sticker shock of GLP-1 medications is real — but the headline number you see quoted in news articles rarely reflects what commercially insured patients actually pay. Understanding the pricing architecture of the U.S. pharmaceutical market is the first step to navigating it effectively.
Wholesale Acquisition Cost (WAC) vs. Net Price
The Wholesale Acquisition Cost (WAC) — sometimes called the list price — is what manufacturers officially charge wholesalers before any negotiation. For Wegovy (semaglutide 2.4mg weekly), this sits at approximately $1,349 per month as of mid-2024. For Ozempic (semaglutide 0.5–2mg weekly for diabetes), WAC is around $936/month. For Mounjaro and Zepbound (tirzepatide), WAC ranges from $1,023–$1,069/month.
But almost nobody pays WAC. The net price — what manufacturers actually receive after rebates paid to pharmacy benefit managers (PBMs), insurers, and the government — is typically 50–70% lower than WAC for major GLP-1 medications, according to manufacturer filings and IQVIA analysis.
How PBM Rebates Work
Pharmacy Benefit Managers (PBMs) like Express Scripts, CVS Caremark, and OptumRx negotiate rebates from drug manufacturers in exchange for favorable formulary placement. A manufacturer might pay a PBM a 40% rebate in exchange for Tier 2 (preferred brand) status rather than Tier 3 (non-preferred).
The problem: these rebates often flow to employers and insurers, not directly to patients at the pharmacy counter. Your out-of-pocket cost is calculated on the WAC, not the post-rebate net price — a phenomenon critics call the "rebate trap." This is one reason patients with high-deductible plans can face enormous costs even when their employer is receiving substantial rebates from manufacturers.
Why List Price Gets Quoted So Often
News coverage, patient advocacy groups, and congressional hearings typically cite WAC because it is the only publicly available price point. Actual net prices are considered proprietary business information and are not publicly disclosed by manufacturers or PBMs. The opacity is intentional and has been the subject of increasing regulatory scrutiny under the Inflation Reduction Act and FTC investigations into PBM practices.
2. Insurance Coverage Landscape: ACA Plans, Employer Plans, Medicare, and State Mandates
Commercial Insurance: ACA Marketplace and Employer Plans
Coverage for GLP-1 medications on commercial plans depends on two variables that rarely align: the indication (diabetes vs. obesity) and the plan design (formulary tier and covered benefit categories).
For type 2 diabetes (Ozempic, Mounjaro): Most commercial plans cover semaglutide and tirzepatide when prescribed for T2D, typically at Tier 2 or Tier 3, with prior authorization. The clinical case is well-established and FDA-approved, and competing medications (Januvia, metformin, SGLT-2 inhibitors) are already covered, creating formulary competition that favors coverage.
For obesity/weight management (Wegovy, Zepbound): Coverage is dramatically less consistent. A 2023 KFF analysis found that fewer than half of large employer plans covered anti-obesity medications (AOMs). The FDA-approved obesity indications require separate prior authorization criteria and are often excluded via explicit benefit exclusions in plan documents.
The Medicare Gap: Weight-Loss Drug Exclusion
Medicare's coverage of GLP-1s for obesity remains the most significant policy gap in the U.S. healthcare system for this drug class. Section 1927(d)(2)(A) of the Social Security Act explicitly excludes "agents when used for anorexia, weight loss, or weight gain" from Medicare Part D coverage.
This exclusion predates GLP-1 medications and was written during an era of unproven stimulant-based diet drugs. The Biden administration proposed a rule in late 2023 to allow Medicare Part D to cover AOMs for obesity when clinically indicated, which, if finalized, would represent a seismic shift in access for Medicare beneficiaries.
State Mandates: The Emerging Landscape
Several states have enacted or proposed mandates requiring coverage of anti-obesity medications for state-regulated (non-ERISA) plans:
- Illinois: Enacted coverage mandate for anti-obesity medications for state-regulated plans, effective 2024
- Minnesota: Enacted coverage requirement for BMI ≥35 with comorbidity on state-regulated plans
- Maryland, New York, Colorado: Proposed or pending legislation as of 2024
Critical limitation: State insurance mandates apply only to fully-insured state-regulated plans. Approximately 60% of covered workers are enrolled in self-funded employer plans, which are governed by ERISA and are exempt from state insurance mandates. This is why even in mandate states, many employees find their coverage unchanged.
The Diagnosis Code Difference: E11 vs. E66
One of the most impactful factors in coverage decisions is which ICD-10 code appears on your prior authorization and prescription. E11.xx (Type 2 diabetes mellitus) triggers the diabetes coverage pathway. E66.xx (Obesity) triggers the obesity/AOM pathway, which faces more exclusions and stricter criteria.
Patients with both T2D and obesity who are prescribed Ozempic for glycemic control have a markedly different coverage profile than patients with obesity alone seeking Wegovy. This distinction is not arbitrary — it reflects the historical regulatory and coverage architecture for these indications.
3. Manufacturer Savings Programs: Novo Nordisk, Eli Lilly, and Patient Assistance
Novo Nordisk Savings Cards (Ozempic & Wegovy)
Novo Nordisk offers two primary patient assistance programs for their GLP-1 medications:
Ozempic Savings Card: Commercially insured patients who qualify may pay as little as $25/month for up to 24 months. The savings card applies after insurance pays its portion. Eligibility requires: (1) commercial insurance coverage for Ozempic, (2) no government insurance (Medicare, Medicaid, VA), and (3) income below a threshold that varies annually.
Wegovy Savings Card: Novo Nordisk offers a savings program where eligible patients can pay $0/month for the first month, with ongoing savings for commercially insured patients. Critically, the plan must cover Wegovy for the card to provide maximum benefit — patients with plans that exclude Wegovy entirely may face different terms.
Novo Nordisk Patient Assistance Program (NovoCare): For patients without insurance or who are uninsured and income-qualified, NovoCare may provide Ozempic or Wegovy at no cost. Income eligibility typically requires household income at or below 400% of the federal poverty level. Applications require physician certification and financial documentation.
Eli Lilly Savings Programs (Mounjaro & Zepbound)
Mounjaro Savings Card: Eligible commercially insured patients may pay as little as $25/month for Mounjaro. The program has been in high demand since Mounjaro's approval and savings card availability fluctuates — check LillyDirect.com for current terms.
Zepbound Savings Card: Since Zepbound's approval for obesity in November 2023, Eli Lilly has offered savings programs for commercially insured patients. Lilly also launched LillyDirect, a direct-to-patient pharmacy service that may provide self-pay pricing options, though pricing varies.
Lilly Cares Patient Assistance: Income-qualified uninsured patients may receive Mounjaro or Zepbound at no cost through the Lilly Cares Foundation. Eligibility criteria and application processes are available at LillyCares.com.
4. Prior Authorization Strategy: Criteria, Letters of Medical Necessity, Appeals
What Plans Look for in Prior Authorization
Prior authorization (PA) for GLP-1 medications typically requires documentation of several clinical criteria. While specific requirements vary by payer, the most common criteria for the obesity indication (Wegovy, Zepbound) include:
- BMI ≥30 kg/m² (documented in the medical record, not just reported by patient)
- Or BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, T2D, dyslipidemia, obstructive sleep apnea, cardiovascular disease)
- Documentation of prior lifestyle intervention (diet and exercise counseling, typically 3–6 months)
- Absence of contraindications (personal or family history of medullary thyroid cancer, MEN2)
- For some plans: prior trial of and inadequate response to other anti-obesity medications
For the diabetes indication (Ozempic, Mounjaro), PA criteria are typically less burdensome:
- Confirmed T2D diagnosis (HbA1c ≥7% or similar threshold)
- On metformin or documented intolerance/contraindication to metformin
- Some plans require a trial of older GLP-1 agents (Trulicity, Victoza) before approving semaglutide
- Documentation of cardiovascular disease history may facilitate approval under CVOT data
Crafting an Effective Letter of Medical Necessity
A strong Letter of Medical Necessity (LMN) from your physician can significantly improve PA approval rates and is the single most impactful document in the appeal process. An effective LMN should include:
- Documented clinical measurements: BMI calculation with height and weight, HbA1c, blood pressure, lipid panel — objective data from chart
- Comorbidity list with ICD-10 codes: Every documented condition that supports medical necessity
- Failed conservative therapy: Documented counseling on diet, exercise, behavioral modification with dates
- Clinical guideline citation: AHA/ACC Obesity Guidelines, Endocrine Society, Obesity Medicine Association recommendations
- Clinical rationale: Why this specific medication class is appropriate vs. alternatives
- Long-term clinical risk: Quantified cardiovascular, metabolic, orthopedic, or oncologic risk of untreated obesity/diabetes
The Appeal Process: Internal and External
Federal law (under the ACA) guarantees three levels of appeal for denied health insurance claims:
Level 1 — Internal Appeal: Filed directly with the insurer. You have 180 days from denial. Provide updated clinical documentation, a peer-reviewed literature review supporting the medication, and the physician LMN. Internal appeals are resolved by the insurer's own medical reviewers, who may apply different clinical standards than your physician.
Level 2 — External Review: If the internal appeal is denied and the denial is based on medical necessity (not just a benefit exclusion), you have the right to an independent external review by an accredited organization. External reviewers must apply objective clinical standards, not plan design preferences. External reviews result in reversal of insurer denials in approximately 40% of cases, according to Kaiser Family Foundation data.
Level 3 — State Insurance Commission Complaint: If external review fails or is unavailable (e.g., for ERISA self-funded plans), you can file a complaint with your state insurance commission for state-regulated plans, or with the U.S. Department of Labor for ERISA plans.
5. Compounding Pharmacies and Alternatives: FDA Shortage Removal, 503B Facilities, Biosimilar Timeline
The Compounding Landscape Before April 2024
During the semaglutide drug shortage (which FDA officially recognized starting in 2022), 503A compounding pharmacies (traditional compounding for individual patients) and 503B outsourcing facilities (larger-scale sterile compounding for healthcare institutions) were legally permitted to compound copies of semaglutide products under the drug shortage exemption provided by the Federal Food, Drug, and Cosmetic Act.
This created a significant market for compounded semaglutide — typically offered at dramatically lower prices ($100–$400/month) compared to branded products, and often prescribed through telehealth platforms.
April 2024: The FDA Shortage Removal and Its Consequences
In April 2024, the FDA removed semaglutide from its drug shortage list, concluding that supply had caught up with demand sufficiently to end shortage status. This removal has significant legal implications for compounding pharmacies:
Under 21 U.S.C. § 503A (which governs traditional compounding pharmacies), compounding of essentially a copy of a commercially available drug is prohibited. The drug shortage exemption was a legal carve-out to this prohibition. With semaglutide removed from the shortage list, 503A pharmacies compounding semaglutide injectables lost their primary legal basis.
For 503B outsourcing facilities, which operate under a separate regulatory framework and supply healthcare institutions rather than individual patients, the picture is more complex. FDA issued guidance indicating it would work with 503B facilities on compliance timelines, but the agency's general position is that compounding copies of non-shortage commercially available drugs is not permissible.
Oral Semaglutide: Rybelsus
Rybelsus (oral semaglutide 3mg, 7mg, 14mg) was approved by the FDA for type 2 diabetes management and represents an oral alternative for patients who prefer to avoid injectable GLP-1s. Coverage patterns for Rybelsus generally mirror those for Ozempic, though prior authorization criteria and tier placement vary by plan. Rybelsus is not approved for obesity.
GLP-1 Biosimilar Timeline
Biosimilar competition for semaglutide is likely years away. Ozempic's core composition of matter patent expires in 2031 in the United States, with additional device and formulation patents potentially extending protection further. Novo Nordisk has pursued aggressive patent protection strategies.
Tirzepatide (Mounjaro/Zepbound) patents extend into the mid-2030s. The first GLP-1 biosimilar (targeting liraglutide/Victoza) may arrive earlier, but liraglutide has been largely supplanted by newer agents clinically.
For context on biosimilar development timelines: even after patent expiration, biosimilar development for complex injectable peptides takes 3–7 years of clinical development, regulatory review, and manufacturing scale-up. Patients should not count on biosimilar pricing relief before 2033–2035 at the earliest for semaglutide.
Cost Comparison: Five Coverage Scenarios
Real-world out-of-pocket costs for GLP-1 medications depend heavily on insurance status, plan design, and manufacturer program eligibility. The table below illustrates typical cost scenarios:
| Coverage Scenario | Medication | Monthly Out-of-Pocket | Key Factors | Status |
|---|---|---|---|---|
| Commercial insurance, T2D indication, Tier 2 | Ozempic 1mg | $25–$100 + deductible | Covered for diabetes; savings card may bring to $25; deductible phase increases costs | Best case |
| Commercial insurance with Wegovy coverage, savings card eligible | Wegovy 2.4mg | $0–$25 | Plan covers obesity indication; Novo Nordisk savings card applied; commercially insured | Favorable |
| Commercial insurance, obesity excluded from formulary | Wegovy 2.4mg | $500–$1,349 | Plan explicitly excludes AOMs; savings card provides limited benefit without coverage | Common barrier |
| Medicare Part D, obesity indication | Wegovy 2.4mg | $1,349 (full WAC) | Statutory exclusion for weight-loss drugs; no Part D coverage; Medicare savings cards not applicable | Not covered |
| No insurance, income-qualified, patient assistance | Ozempic or Wegovy | $0 | NovoCare patient assistance; requires application, physician certification, income documentation | Conditional |
8-Step Insurance Navigation Protocol
Use this structured approach to maximize your chances of obtaining GLP-1 coverage and minimizing out-of-pocket costs: